奥泰生物
(688606)
| 流通市值：26.30亿 | | | 总市值：52.72亿 |
| 流通股本：3955.03万 | | | 总股本：7928.09万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 199,920,896.28 | 754,696,888.86 | 559,938,588.88 | 387,847,292.99 |
| 营业收入 | 199,920,896.28 | 754,696,888.86 | 559,938,588.88 | 387,847,292.99 |
| 二、营业总成本 | 144,138,319.97 | 592,083,574.56 | 437,853,772.09 | 305,909,923.16 |
| 营业成本 | 99,702,324.24 | 386,540,797.7 | 291,661,782.03 | 207,101,764.06 |
| 税金及附加 | 2,049,793.49 | 7,037,005.11 | 3,701,949.16 | 2,595,420.16 |
| 销售费用 | 10,813,141.14 | 69,285,218.73 | 47,449,213.41 | 32,643,443.92 |
| 管理费用 | 13,493,416.42 | 66,586,762.42 | 48,453,128.84 | 34,464,317.52 |
| 研发费用 | 23,156,697.04 | 121,169,279.46 | 89,692,899.23 | 65,878,475.97 |
| 财务费用 | -5,077,052.36 | -58,535,488.86 | -43,105,200.58 | -36,773,498.47 |
| 其中:利息费用 | 132,558.32 | 1,448,673.48 | 1,168,205.25 | 833,663.45 |
| 其中:利息收入 | 5,365,092.08 | 35,618,333.76 | 29,487,410.77 | 21,797,730.43 |
| 加:公允价值变动收益 | 3,363,643.08 | 32,668,473.1 | 4,961,782.69 | 1,409,478.93 |
| 加:投资收益 | 4,204,435.81 | 8,634,776.34 | 6,344,240.37 | 6,264,677.25 |
| 资产处置收益 | -6,081.72 | -419,217.85 | -535,166.71 | -535,166.71 |
| 资产减值损失(新) | -5,444,901.01 | 5,601,209.45 | 1,054,711.95 | 4,779,820.28 |
| 信用减值损失(新) | -11,367,660.48 | -11,227,697.68 | -14,111,582.59 | -10,767,071.92 |
| 其他收益 | 796,950.38 | 13,710,450.52 | 9,303,148.23 | 7,986,860.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 47,328,962.37 | 211,581,308.18 | 129,101,950.73 | 91,075,967.92 |
| 加:营业外收入 | 100,000.17 | 24,082.7 | 13,974.92 | 13,974.92 |
| 减:营业外支出 | 271,695.4 | 14,166,640.65 | 14,152,681.81 | 13,827,488.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 47,157,267.14 | 197,438,750.23 | 114,963,243.84 | 77,262,454.1 |
| 减:所得税费用 | 2,512,937.47 | 17,158,142.06 | 13,716,923.17 | 6,435,599.86 |
| 六、净利润 | 44,644,329.67 | 180,280,608.17 | 101,246,320.67 | 70,826,854.24 |
| 持续经营净利润 | 44,644,329.67 | 180,280,608.17 | 101,246,320.67 | 70,826,854.24 |
| 归属于母公司股东的净利润 | 44,788,913.62 | 180,576,190.21 | 101,565,695.05 | 71,181,851.07 |
| 少数股东损益 | -144,583.95 | -295,582.04 | -319,374.38 | -354,996.83 |
| (一)基本每股收益 | 0.56 | 2.28 | 1.28 | 0.9 |
| (二)稀释每股收益 | 0.56 | 2.28 | 1.28 | 0.9 |
| 八、其他综合收益 | 151,351.08 | 2,367,625.72 | 3,883,900.18 | 4,758,574.54 |
| 归属于母公司股东的其他综合收益 | 144,607.76 | 2,363,130.17 | 3,881,246.16 | 4,754,344.63 |
| 九、综合收益总额 | 44,795,680.75 | 182,648,233.89 | 105,130,220.85 | 75,585,428.78 |
| 归属于母公司股东的综合收益总额 | 44,933,521.38 | 182,939,320.38 | 105,446,941.21 | 75,936,195.7 |
| 归属于少数股东的综合收益总额 | -137,840.63 | -291,086.49 | -316,720.36 | -350,766.92 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-31 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |